Latest news

• Novartis' Ilaris wins three new FDA approvals

  The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.

• Grunenthal to market MSD’s pain drug

  The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.

• Novartis wins childhood arthritis indication for Ilaris in EU

  EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... gouty arthritis, which is a painful inflammation of the joints.

• Novartis gets FDA green light for new Ilaris indication

  Immunotherapeutic wins US approval for severe form of childhood arthritis. The US FDA has cleared another indication for Novartis' fast-growing immunotherapeutic Ilaris, this time giving the nod to its use ... arthritis. Efforts to get a gouty arthritis

• Novartis' Ilaris cleared for gouty arthritis in EU

  First biologic drug approved for condition in Europe. Novartis' Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another ... The European Commission (EC) cleared llaris (canakizumab) for the